Fungal Endocarditis Market Trends

Fungal Endocarditis Market Overview

Fungal Endocarditis Market Size was valued at USD 0.378 Billion in 2023. The Global Fungal Endocarditis industry is projected to grow from USD 0.45 Billion in 2024 to USD 0.673 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.43% during the forecast period (2024 - 2032).Fungal endocarditis is a rare and extremely enfeebling disease associated with high rate of mortality of around 50%. The condition is usually being diagnosed postmortem. The etiologic fungi more commonly observed are the Candida and Aspergillus species.

As per the study published in the International Cardiovascular Research Journal in 2014, it is found that Candida albicans, and Aspergillus species are the most frequent cause of fungal endocarditis. Candida albicans is found to be responsible for 24%-46% of cases of fungal endocarditis, and for 3.4% of the prosthetic valve endocarditis cases with associated mortality rates of 46.6%-50%. After Candida, Aspergillus species is the second most common cause of fungal endocarditis, accounting for nearly 25% of the cases of fungal endocarditis in cardiac valve prostheses and the great vessels.

With an increasing age, the incidence of Candida fungal endocarditis decreases whereas the incidence of Aspergillus fungal endocarditis increases. The affected cardiac sites in neonates is significantly different from the adults with the right atrium being predominant in 63% of neonates

The possible complications associated with fungal endocarditis are congestive heart failure, mitral and aortic valve incompetence, neurological complications, formation of myocardial abscesses, and metastatic infections. According to a study published in PLOS one in 2013, it is found that the incidence of hospitalization for fungal endocarditis in the United States is 12.7 per 100,000 annually.

Notably, rising awareness about fungal infections is the key factor driving the fungal endocarditis market. Nowadays, people are becoming more aware about the different types of fungal infections. Government and other different organizations have started educating people about the hygiene and infectious diseases. People are becoming more aware and conscious about the diseases. Thus, increasing awareness has provided a push to the growth of the market.

Various other push factors such as increasing incidents of fungal infections, increasing government assistance, improving regulatory framework, and rising funding and reimbursement continuously contributing to the growth of the fungal endocarditis market.

Despite these drivers, there are some issues associated with fungal endocarditis market. Some of the challenges in research and development are side-effects of treatment, presence of misbranded and spurious drugs, and poor healthcare system in low and middle-income countries, which may hinder the growth of the market to an extent. In contrast to the remedial effects, antifungal treatment can have many side effects as well. Some of them include: irritation, itching, headache, diarrhoea, and anaemia. They are also responsible for causing kidney and liver damage. Beside this, many antifungal medicines can cause allergic reactions, thus, they are not prescribed to pregnant women and children.

It is estimated that the fungal endocarditis market is expected to grow at a CAGR 5.43% during the forecast period of 2024-2032.

April 2024: Merck made public positive results through a phase III study of V116, its antifungal medicine against invasive pneumococcal diseases. Furthermore, Merck is diving deep for the utilization of Keytruda as an adjunct to variation therapy with anti-fungals in targeting particular cancers.

Merck’s development of new antifungal therapies is underscored by its ongoing discovery as well as clinical trials mainly for addressing drug-resistant fungus diseases​​ on April 2024.

2023: Pfizer launched Cresemba (isavuconazole), an antifungal agent effective in various invasive mycoses, that include Aspergillus and Mucorales species. The effort supports Pfizer’s idea to enhance its anti-infectives portfolio and address unmet medical needs in the field of antifungal treatments​​.

SCYNEXIS has been appreciated on November 2022 by BARDA for its modern broad-spectrum MK-3118. This property makes it special since it targets many resistant strains like Candida auris and Aspergillus species. SCYNEXIS is currently undertaking phase three investigations with the aim of meeting this urgent need for new antifungal drugs​.

ContraFect Corporation, a company operating at late-stage clinical trials specializing in biotechnology, said yesterday that they have begun an expanded access program for exebacase treatment of sustained bacteremia caused by methicillin-resistant Staphylococcus aureus as declared last month during October 2020.

Exebacase is presently undergoing Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) superiority design study in patients with Staph aureus bacteremia, inclusive of right-sided endocarditis.

Intended Audience

• Pharmaceutical Companies


• Research and Development (R&D) Companies


• Diagnostic Laboratories


• Government Research Institute


• Academic Institutes and Universities

Fungal Endocarditis Market Segmentation

The fungal endocarditis market is segmented on the basis of type of causative agent, diagnosis, treatment, and end-user.

Fungal Endocarditis Type Insights

On the basis of the type of causative agent, the market is segmented into Candida species, Aspergillus species, and Histoplasma capsulatum.

Fungal Endocarditis Diagnosis Insights

On the basis of the diagnosis, the market is classified into physical examination, blood test, X-ray, echocardiography, and electrocardiogram

Fungal Endocarditis Treatment Insights

On the basis of the treatment, the market is classified as antifungal medication, surgery, and combined treatment. The antifungal medication is further segmented into voriconazole, amphotericin B (AMB), itraconazole, caspofungin, echinocandins, and others.

Fungal Endocarditis End-Users Insights

On the basis of the end-users, the market is segmented into hospital, clinics, diagnostic centers, and others.

Regional Analysis

The Americas dominate the fungal endocarditis market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.

Europe holds the second position in the fungal endocarditis market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive the market of Europe region.

The Asia Pacific is the fastest growing fungal endocarditis market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.

The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.

Key Players

Some of key the players in the fungal endocarditis market are 

• Pfizer, 


• Merck & Co., 


• Sanofi, 


• Astellas Pharma, Inc., 


• GlaxoSmithKline plc, 


• Novartis AG, 


• Enzon Pharmaceuticals, Inc., 


• Bayer AG, 


• Sigma-Aldrich, 


• Abbott Laboratories, 


• Eli Lily and Company, and 


• Others. 

Research Methodology